

# SDRA : Analyse critique des nouvelles recommandations

Alain Mercat alain.mercat@univ-angers.fr













## Liens d'intérêts

- Financement travaux de recherche
  - General Electric
- Rémunérations d'interventions
  - Getinge
  - Fisher Paykel
  - Dräger Medical
- Rémunérations de consultant
  - Air Liquide Medical Systems
  - Bayer

# **Acute Respiratory Distress Syndrome**

The Berlin Definition

The ARDS Definition Task Force\* JAMA, June 20, 2012—Vol 307, No. 23

	Acute Respiratory Distress Syndrome		
Timing	Within 1 week of a known clinical insult or new/worsening respiratory symptoms		
Chest Imaging	Bilateral opacities – not fully explained by effusions, lobar/lung collapse, or nodules		
Origin of Edema	Respiratory failure not fully explained by cardiac failure or fluid overload;  Need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present		
	Mild	Moderate	Severe
Oxygenation b	200< $PaO_2/FiO_2 \le$ 300 with PEEP or CPAP $\ge 5$ cm $H_2O^c$	100 <pao<sub>2/FiO<sub>2</sub>≤200 with PEEP ≥ 5 cmH<sub>2</sub>O</pao<sub>	PaO <sub>2</sub> /FiO2≤100 with PEEP $\geq$ 5 cmH <sub>2</sub> O



# A New Global Definition of Acute Respiratory Distress Syndrome

Michael A. Matthay<sup>1,2,3</sup>, Yaseen Arabi<sup>5</sup>, Alejandro C. Arroliga<sup>6</sup>, Gordon Bernard<sup>7</sup>, Andrew D. Bersten<sup>9</sup>, Laurent J. Brochard<sup>10</sup>, Carolyn S. Calfee<sup>1,2,3</sup>, Alain Combes<sup>11</sup>, Brian M. Daniel<sup>4</sup>, Niall D. Ferguson<sup>12,13</sup>, Michelle N. Gong<sup>14</sup>, Jeffrey E. Gotts<sup>15</sup>, Margaret S. Herridge<sup>16</sup>, John G. Laffey<sup>17</sup>, Kathleen D. Liu<sup>1,2</sup>, Flavia R. Machado<sup>18</sup>, Thomas R. Martin<sup>19</sup>, Danny F. McAuley<sup>20</sup>, Alain Mercat<sup>21</sup>, Marc Moss<sup>22</sup>, Richard A. Mularski<sup>23</sup>, Antonio Pesenti<sup>24,25</sup>, Haibo Qiu<sup>26</sup>, Nagarajan Ramakrishnan<sup>27</sup>, V. Marco Ranieri<sup>28</sup>, Elisabeth D. Riviello<sup>29</sup>, Eileen Rubin<sup>30</sup>, Arthur S. Slutsky<sup>10</sup>, B. Taylor Thompson<sup>31</sup>, Theogene Twagirumugabe<sup>32</sup>, Lorraine B. Ware<sup>8</sup>, and Katherine D. Wick<sup>33</sup>

Am J Respir Crit Care Med 2023 Jul 24. DOI: 10.1164/rccm.202303-0558WS.

Risk factors and	Precipitated by an acute predisposing risk factor such as pneumonia, non-pulmonary infection,		
origin of edema	trauma, transfusion, aspiration, or shock. Pulmonary edema is not exclusively or primarily		
	attributable to cardiogenic pulmonary edema/fluid overload, and hypoxemia/gas exchange		


the presence of these conditions if a predisposing risk factor for ARDS is also present. Timing Acute onset or worsening of hypoxemic respiratory failure within 1 week of the estimated onset of the predisposing risk factor or new or worsening respiratory symptoms. Chest Imaging Bilateral opacities on chest radiograph, computed tomography, of ultrasound not fully explained


by effusions, atelectasis, or nodules/masses. Criteria that apply to specific ARDS categories Non-intubated ARDS

## Oxygenation<sup>3,4</sup> $PaO_2/FiO_2 \le 300 \text{ mmHg or}$ $SpO_2/FiO_2 \le 315$ (if

or NIV/CPAP with at least 5

SpO<sub>2</sub>≤97%) on HFNO with a flow of  $\geq$  30 liters per minute cm H<sub>2</sub>O expiratory pressure





(if SpO<sub>2</sub>≤97%)


SpO<sub>2</sub>≤97%)


 $PaO_2/FiO_2 \le 100 \text{ or}$  $SpO_2/FiO_2 \le 148$  (if

Severe:

Criteria that apply to all ARDS categories


abnormalities are not primarily attributable to atelectasis. However, ARDS can be diagnosed in





# **Patient Description**

68 M with abdominal sepsis, septic shock, and acute hypoxemic respiratory failure



**Imaging** 

Mechanically ventilated FiO<sub>2</sub> 0.5 PaO<sub>2</sub> 75 P/F = 150

Oxygenation

Intubated ARDS Severity: Moderate Typical patient included in prior Berlin definition

**ARDS Categories** 



54 F with history of breast cancer, COVID-19 pneumonia, and worsening SOB for the past 6 days



High flow nasal oxygen HFNO 40L/min FiO<sub>2</sub> 0.80 SpO<sub>2</sub> 91% S/F = 114

Non-Intubated ARDS New category in Global definition



39 F with abdominal sepsis and gram negative bacteremia in a small under-resourced hospital without blood gases, radiography or mechanical ventilation



Supplemental oxygen by face mask at 15L/min FiO<sub>2</sub> 0.6 SpO<sub>2</sub> 85% S/F = 142

ARDS in resource-variable settings

New category in Global definition, consistent with Kigali modification

An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome

Am J Respir Crit Care Med Vol 195, Iss 9, pp 1253-1263, May 1, 2017

REVIEW Open Access

# Formal guidelines: management of acute respiratory distress syndrome



Laurent Papazian<sup>1\*</sup>, Cécile Aubron<sup>2</sup>, Laurent Brochard<sup>3</sup>, Jean-Daniel Chiche<sup>4</sup>, Alain Combes<sup>5</sup>, Didier Dreyfuss<sup>6</sup>, Jean-Marie Forel<sup>1</sup>, Claude Guérin<sup>7</sup>, Samir Jaber<sup>8</sup>, Armand Mekontso-Dessap<sup>9</sup>, Alain Mercat<sup>10</sup>, Jean-Christophe Richard<sup>11</sup>, Damien Roux<sup>6</sup>, Antoine Vieillard-Baron<sup>12</sup> and Henri Faure<sup>13</sup>

Ann. Intensive Care


(2019) 9:69

### Early management of ARDS in 2019



Should not be done

> HEOV



#### **CONFERENCE REPORTS AND EXPERT PANEL**



# ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies

Giacomo Grasselli<sup>1,2\*</sup>, Carolyn S. Calfee<sup>3</sup>, Luigi Camporota<sup>4,5</sup>, Daniele Poole<sup>6</sup>, Marcelo B. P. Amato<sup>7</sup>. Massimo Antonelli<sup>8,9</sup>, Yaseen M. Arabi<sup>10,11,12</sup>, Francesca Baroncelli<sup>13</sup>, Jeremy R. Beitler<sup>14</sup>, Giacomo Bellani<sup>15,16</sup>, Geoff Bellingan<sup>17</sup>, Bronagh Blackwood<sup>18</sup>, Lieuwe D. J. Bos<sup>19</sup>, Laurent Brochard<sup>20,21</sup>, Daniel Brodie<sup>22</sup>, Karen E. A. Burns<sup>21,23,24,25</sup>, Alain Combes<sup>26,27</sup>, Sonia D'Arrigo<sup>8</sup>, Daniel De Backer<sup>28</sup>, Alexandre Demoule<sup>29,30</sup>, Sharon Einav<sup>31</sup>, Eddy Fan<sup>21</sup>, Niall D. Ferguson<sup>32,33</sup>, Jean-Pierre Frat<sup>34,35</sup>, Luciano Gattinoni<sup>36</sup>, Claude Guérin<sup>37,38</sup>, Margaret S. Herridge<sup>39</sup>, Carol Hodgson<sup>40,41</sup>, Catherine L. Hough<sup>42</sup>, Samir Jaber<sup>43</sup>, Nicole P. Juffermans<sup>44</sup>, Christian Karagiannidis<sup>45</sup>, Jozef Kesecioglu<sup>46</sup>, Arthur Kwizera<sup>47</sup>, John G. Laffey<sup>48,49</sup>, Jordi Mancebo<sup>50</sup>, Michael A. Matthay<sup>51</sup>, Daniel F. McAuley<sup>18,52</sup>, Alain Mercat<sup>53</sup>, Nuala J. Meyer<sup>54</sup>, Marc Moss<sup>55</sup>, Laveena Munshi<sup>56</sup>, Sheila N. Myatra<sup>57</sup>, Michelle Ng Gong<sup>58,59</sup>, Laurent Papazian<sup>60,61</sup>, Bhakti K. Patel<sup>62</sup>, Mariangela Pellegrini<sup>63</sup>, Anders Perner<sup>64</sup>, Antonio Pesenti<sup>1,2</sup>, Lise Piquilloud<sup>65</sup>, Haibo Qiu<sup>66</sup>, Marco V. Ranieri<sup>67,68</sup>, Elisabeth Riviello<sup>69</sup>, Arthur S. Slutsky<sup>21,24</sup>, Renee D. Stapleton<sup>70</sup>, Charlotte Summers<sup>71</sup>, Taylor B. Thompson<sup>72</sup>, Carmen S. Valente Barbas<sup>73,74</sup>, Jesús Villar<sup>24,75,76</sup>, Lorraine B. Ware<sup>77</sup>, Björn Weiss<sup>78</sup>, Fernando G. Zampieri<sup>79,80</sup>, Elie Azoulay<sup>81</sup> and Maurizio Cecconi<sup>82,83</sup> on behalf of the European Society of Intensive Care Medicine Taskforce on ARDS

# ARDS guidelines ESICM 2023

- Pendant la pandémie Covid
- Plus de 60 experts internationaux, 3 méthodologistes, 8 représentants des patients
- Innombrables e-mails, multiples réunions (visioconférences)
- Méthodologie très stricte (!!!): PICO, PRISMA, GRADE
- 9 domaines : Définition, phénotypes, HDN, CPAP/VNI, VT, PEEP-RM, DV, curares, ECMO-ECCO<sub>2</sub>R
- 1 à 5 questions par domaine → 16 « recommandations »
- Article (32 pages) + supplément « online » (307 pages !!)

# ARDS guidelines ESICM 2023

- Patient
- Intervention
- **C**omparateur
- **O**utcome

# GRADE

- Niveau de preuve (RCT +++)
- Importance clinique et ampleur de l'effet, coût, disponibilité
- Force de la recommandation

Opinions des experts

# Haut débit nasal vs O<sub>2</sub> conventionnel

#### **Recommendation 3.1**

We **recommend** that non-mechanically ventilated patients with AHRF not due to cardiogenic pulmonary edema or acute exacerbation of COPD receive HFNO as compared to conventional oxygen therapy to reduce the risk of intubation Strong recommendation; moderate level of evidence in favor

We are **unable to make a recommendation** for or against the use of HFNO over conventional oxygen therapy to reduce mortality *No recommendation; high level of evidence of no effect* 

This recommendation applies also to AHRF from COVID-19 Strong recommendation; low level of evidence in favor for intubation and no recommendation; moderate level of evidence of no effect for mortality, for indirectness.

# CPAP/VNI vs O<sub>2</sub> conventionnel

#### **Recommendation 4.1**

We are **unable to make a recommendation** for or against the use of CPAP/NIV compared to conventional oxygen therapy for the treatment of AHRF (not related to cardiogenic pulmonary edema or acute exacerbation of COPD) to reduce mortality or to prevent intubation.

No recommendation; high level of evidence for mortality, moderate level of evidence for intubation.

We **suggest** the use of CPAP over conventional oxygen therapy to reduce the risk of intubation in patients with acute hypoxemic respiratory failure due to COVID-19.

Weak recommendation; low level of evidence in favor.

In this population, we are **unable to make a recommendation** for or against the use of CPAP over conventional oxygen therapy to reduce mortality.

No recommendation; moderate level of evidence of no effect.

# Haut débit nasal vs CPAP/VNI

#### **Recommendation 3.2**

We are **unable to make a recommendation** for or against the use of HFNO compared to continuous positive airway pressure (CPAP)/NIV to reduce intubation or mortality in the treatment of unselected patients with acute hypoxemic respiratory failure not due to cardiogenic pulmonary edema or acute exacerbation of COPD. No recommendation; moderate level of evidence for mortality, low level of evidence for intubation, not in favor nor against.

We **suggest** that CPAP/NIV can be considered instead of HFNO for the treatment of AHRF due to COVID-19 to reduce the risk of intubation (*weak recommendation*, *high level of evidence*), but **no recommendation** can be made for whether CPAP/NIV can decrease mortality compared to HFNO in COVID-19. *No recommendation; high level of evidence of no effect.* 

# VT: Rien de nouveau

# **Recommendation 5.1**

We **recommend** the use of low tidal volume ventilation strategies (i.e., 4–8 ml/kg PBW), compared to larger tidal volumes (traditionally used to normalize blood gases), to reduce mortality in patients with ARDS not due to COVID-19.

Strong recommendation based on expert opinion despite lack of statistical significance; high level of evidence.

This recommendation applies also to ARDS from COVID-19. Strong recommendation; moderate level of evidence for indirectness.

# PEEP: Rien

#### **Recommendation 6.1**

We are **unable to make a recommendation** for or against routine PEEP titration with a higher PEEP/FiO<sub>2</sub> strategy versus a lower PEEP/FiO<sub>2</sub> strategy to reduce mortality in patients with ARDS. *No recommendation; high level of evidence of no effect.* 

This statement applies also to ARDS from COVID-19. No recommendation; moderate level of evidence of no effect for indirectness.


#### **Recommendation 6.2**

We are **unable to make a recommendation** for or against PEEP titration guided principally by respiratory mechanics, compared to PEEP titration based principally on PEEP/FiO<sub>2</sub> strategy, to reduce mortality in patients with ARDS.

No recommendation; high level of evidence of no effect.

This statement applies also to ARDS from COVID-19. *No recommendation; moderate level of evidence for indirectness.* 

# PEEP: Rien



# Manœuvres de recrutement : Non

# **Recommendation 6.3**

We **recommend against** use of prolonged high-pressure recruitment maneuvers (defined as airway pressure maintained  $\geq$  35 cmH<sub>2</sub>O for at least one minute) to reduce mortality of patients with ARDS.

Strong recommendation; moderate level of evidence against.

This recommendation applies also to ARDS from COVID-19. Strong recommendation; low level of evidence against for indirectness.

DV : C'est clair (mais pas nouveau et pas appliqué!)

## **Recommendation 7.1**

We **recommend** using prone position as compared to supine position for patients with moderate-severe ARDS (defined as  $PaO_2/FiO_2 < 150$  mmHg and  $PEEP \ge 5$  cmH<sub>2</sub>O, despite optimization of ventilation settings) to reduce mortality. Strong recommendation, high level of evidence in favor.

This recommendation applies also to ARDS from COVID-19. Strong recommendation; moderate level of evidence in favor for indirectness.

# Que faire de tout ça?

- Lire l'article (pas seulement les recommandations)
- S'approprier ou non les recommandations > Procédure de service
- Vérifier-mesurer ce que l'on fait → Evaluation
- Se remettre en cause → Adaptation
- Contribuer à répondre aux questions non résolues
  - → Recherche clinique

#### **EDITORIAL**



# Back to the future: ARDS guidelines, evidence, and opinions

Luciano Gattinoni<sup>1\*</sup>, Giuseppe Citerio<sup>2,3</sup> and Arthur S. Slutsky<sup>4,5</sup>

Intensive Care Med (2023) 49:1226–1228

« To set the ventilator in ARDS, you must first connect your brain »

L. Gattinoni, ESICM meeting. Milan 2016

